The Evolution of Incretin Based Research
The discovery of incretin hormones revolutionised our understanding of metabolic regulation. GLP 1 (Glucagon Like Peptide 1) and GIP (Glucose Dependent Insulinotropic Polypeptide) are the two primary incretin hormones, both released from the gut in response to nutrient intake. While GLP 1 receptor agonists like Semaglutide have been extensively studied, Tirzepatide represents the next evolution: a single molecule that activates both GIP and GLP 1 receptors.
Mechanism of Action
Tirzepatide is a 39 amino acid synthetic peptide that acts as a dual agonist at both the GIP and GLP 1 receptors. Its molecular design incorporates:
GIP Receptor Agonism: Tirzepatide shows potent activity at the GIP receptor, which is involved in insulin secretion, lipid metabolism, and adipose tissue function. GIP receptor activation may enhance the metabolic effects beyond what GLP 1 agonism alone can achieve.
GLP 1 Receptor Agonism: Like established GLP 1 agonists, Tirzepatide activates GLP 1 receptors, promoting insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central mechanisms.
Fatty Acid Modification: Tirzepatide incorporates a C20 fatty diacid moiety that enables binding to albumin, extending its half life to approximately 5 days. This allows for once weekly dosing in research protocols.
Key Research Findings
SURPASS Clinical Programme
The SURPASS clinical trial programme represents one of the largest and most comprehensive evaluations of any metabolic compound:
SURPASS 1: Demonstrated significant HbA1c reductions and weight loss as monotherapy
SURPASS 2: Showed superiority over Semaglutide 1mg in head to head comparison
SURPASS 3: Demonstrated superiority over insulin degludec
SURPASS 4: Showed superiority over insulin glargine
SURPASS 5: Demonstrated efficacy as add on to insulin glargine
SURMOUNT Programme
The SURMOUNT trials specifically evaluated Tirzepatide for weight management:
| Trial | Key Finding |
|---|---|
| SURMOUNT 1 | Up to 22.5% body weight reduction |
| SURMOUNT 2 | Significant weight loss in type 2 diabetes |
| SURMOUNT 3 | Sustained effects with lifestyle intervention |
| SURMOUNT 4 | Weight regain prevention data |
Tirzepatide vs Semaglutide
The comparison between Tirzepatide and Semaglutide is one of the most discussed topics in metabolic research:
Efficacy: Head to head data from SURPASS 2 showed Tirzepatide achieved greater HbA1c reductions and weight loss compared to Semaglutide 1mg across all dose levels.
Mechanism: While Semaglutide is a pure GLP 1 receptor agonist, Tirzepatide's dual agonism at both GIP and GLP 1 receptors may provide additional metabolic benefits through complementary pathways.
Tolerability: Both compounds share similar GI side effect profiles, though some research suggests the GIP component of Tirzepatide may help mitigate certain GLP 1 related side effects.
Future Directions
Research into Tirzepatide continues to expand into new therapeutic areas:
- Cardiovascular outcomes (SURPASS CVOT)
- Non alcoholic steatohepatitis (NASH)
- Heart failure with preserved ejection fraction
- Obstructive sleep apnoea
Conclusion
Tirzepatide represents a landmark advancement in metabolic research. Its dual mechanism of action, impressive clinical data, and expanding research applications position it as one of the most important peptides in modern pharmaceutical science.
All products are for research purposes only. Not for human consumption.